Tecfidera Succeeds in Protecting Biogen's MS Market Share From Novartis' Gilenya

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Biogen's (NASDAQ: BIIB  ) Tecfidera is on its way to blockbuster status in the highly competitive multiple sclerosis indication. That's great news for Biogen, which needed the drug to succeed in order to protect its multibillion-dollar multiple sclerosis drug franchise.

An important win
The MS treatment market has previously been dominated by Biogen's Avonex and Tysabri, and Teva Pharmaceutical's Copaxone -- blockbuster drugs delivered by injection. Combined, those drugs generated sales of $8 billion in 2012.

But, a new generation of drugs and upcoming patent expiration for Copaxone are disrupting current treatment protocols and shifting demand to new oral drugs including Novartis' (NYSE: NVS  ) Gilenya and Sanofi's (NYSE: SNY  ) Aubagio.

Those new drugs have been winning share against Biogen with Novartis' Gilenya, approved in 2010, generating sales of $518 million in the third quarter, up 63% year-over-year. Novartis sales for Gilenya increased 44% in the U.S. and 90% in the rest of the world from a year ago.

Sanofi's Aubagio, approved in September 2012, had third-quarter sales of 44 million euros, representing solid growth given combined sales for the first half of the year were 53 million euros.

At the same time, growth for Biogen's legacy Avonex and Tysabri has stalled. Avonex sales slipped 4% year-over-year to $733 million, and Tysabri sales were flat at $403 million. 

As a result, Biogen needed Tecfidera to succeed in order to solidify the company's MS franchise and shift the company back to sales growth for the indication.

A blockbuster in the making
Last week, I suggested you watch Biogen's third-quarter report closely for signs Tecfidera may live up to those high hopes. The early results suggest Tecfidera could become a blockbuster by the middle of next year.

In the quarter, Tecfidera racked up $286 million in sales, more than industry forecasts, according to ISI Group. The performance comes following reports of shortages in the second quarter as wholesalers built up inventory.

It also suggests that payers aren't balking at the drug's $54,000 a year price tag, a price slightly lower than Novartis Gilenya's $58,000, but higher than prior-generation drugs Avonex and Tysabri.

The Foolish final take
Tecfidera comes at an important time to solidify Biogen's MS franchise. Given the significant sales up for grabs from legacy injectibles, Tecfidera's robust third-quarter performance leapfrogs Novartis' Gilenya, making it the top-selling oral MS drug.

That performance is more impressive when you consider the drug is only approved in the U.S., Canada, and Australia. Sales will climb significantly once Tecfidera wins approval in other key developed markets including the EU and Japan.

Of course, any number of events can derail growth, which could shift demand back to Novartis' Gilenya. You need only look back to Tysabri's safety risks following its launch for an example. But for now, it appears Biogen's Tecfidera will protect its MS franchise.

One growth stock you shouldn't overlook
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!

Read/Post Comments (2) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 03, 2013, at 1:03 PM, mcclint67 wrote:

    I'm absolutely disgusted by the greed of the drug companies. My MS drug costs 4600 per month. I have had little to no flare ups in the past 19 years, so yes it is working. I can't wrap my head around the fact that the companies take advantage of the sick to gain a profit

  • Report this Comment On November 11, 2013, at 2:23 AM, ethanspapa wrote:

    Biogen is a 300 dollar stock.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2705290, ~/Articles/ArticleHandler.aspx, 9/25/2016 2:05:55 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
BIIB $312.58 Down -2.23 -0.71%
Biogen CAPS Rating: *****
NVS $81.48 Down -0.55 -0.67%
Novartis CAPS Rating: ****
SNY $38.35 Down -0.22 -0.57%
Sanofi CAPS Rating: *****